(Fighting New Coronary Pneumonia) The follow-up study of the new coronavirus vaccination in Mainland China exceeds 1 billion doses is still to be completed

  China News Service, Beijing, June 20 (Reporter Li Chun) According to data released by the National Health Commission of China on the 20th, as of June 19, 31 provinces (autonomous regions and municipalities directly under the Central Government) and Xinjiang Production and Construction Corps have reported cumulative vaccination The number of new coronavirus vaccines exceeded 1 billion doses, reaching 1.01048.9 million.

Drawing: Li Xueyao

  Combining the data shows that the time taken for every 100 million doses of the new coronavirus vaccine in mainland China is gradually shortening.

From the 100 million doses on March 27th to 500 million doses on May 23, the intervals for breaking the "100 million" dose were 25 days, 16 days, 9 days, and 7 days.

Since May 23, the time required for every 100 million doses of vaccine has been reduced to 5 or 6 days.

  During the academician conference of the two academies at the end of May, Zhong Nanshan, an academician of the Chinese Academy of Engineering, pointed out in an interview with a reporter from China News Agency that based on the vaccine protection rate reaching 70%, China's new crown vaccine coverage rate needs to reach nearly 80% to form herd immunity. .

"As far as I know, at the beginning of July, the country should reach (coverage) 40%, and 80% by the end of this year."

  Zeng Yixin, deputy director of the National Health Commission, also told the media on June 7 that China has 21 new crown vaccines in clinical trials.

It is expected that at least 70% of the target population will be vaccinated before the end of this year.

  Ensuring coverage of vaccines is inseparable from adequate supply of vaccines.

At the Boao Forum for Asia Global Health Forum held earlier this month, Zheng Zhongwei, head of the Vaccine R&D Team of the Joint Prevention and Control Mechanism Research Team of the State Council, reiterated that China’s new crown virus vaccine production capacity will reach 5 billion doses this year, and the output will exceed 3 billion doses. And the number is still increasing with the efforts of enterprises.

  On the other hand, the increase in the amount of new crown vaccination may benefit from the expansion of the scope of vaccination.

Relevant Chinese authorities have approved the emergency use of inactivated COVID-19 vaccines for people aged 3 to 17 years old.

The State Council’s Joint Prevention and Control Mechanism has specially formulated technical guidelines for vaccinations against the new crown virus, guiding local governments to do a good job in vaccinating various groups of people, including the elderly over 60.

  In addition, a more convenient way of administration may also promote the improvement of vaccine coverage.

Also at the beginning of this month, Chen Wei, a researcher at the Chinese Academy of Military Sciences and an academician of the Chinese Academy of Engineering, revealed when attending the Pujiang Innovation Forum that the nebulized inhaled new crown vaccine developed by his team is applying for emergency use authorization from the State Food and Drug Administration.

The vaccine only needs one-fifth of the dose of the vaccine, and the bottleneck problem of the vaccine bottle can be solved without the need to bottle one bottle.

  According to the press conference of the Joint Prevention and Control Mechanism of the State Council on June 11, the relevant research and development units in China are carrying out the development of nasal spray or atomized new crown vaccine as planned, and phase I and phase II clinical trials are already in progress to evaluate this administration. The safety and immunogenicity of the method will be further verified in phase III clinical trials or emergency use.

  Shao Yiming, a researcher at the Chinese Center for Disease Control and Prevention, said that the formulation of the aerosol-inhaled vaccine has not changed, only the method of aerosol inhalation is used instead of intramuscular injection.

In addition, a nasal spray attenuated influenza virus carrier new crown vaccine has also completed phase I and phase II clinical trials, and is applying for overseas phase III clinical trials.

  Regarding the issue of supplementary vaccination of public concern, Wang Huaqing, chief expert of the Chinese Center for Disease Control and Prevention's immunization program, recently stated that the decline in the level of vaccine antibodies does not mean that there is no protection, and follow-up related research is needed.

The top priority is to establish a herd immunity barrier and eliminate the immune gap.

  The expert also pointed out that more research needs to be done on whether and how to strengthen immunity in the follow-up.

It is also necessary to obtain more sufficient evidence to decide whether to adjust the current immunization strategy.

"To evaluate safety, we can only decide whether to boost immunity after comprehensively obtaining sufficient evidence. Therefore, there are still many studies to be completed in the follow-up." (End)